Correlation Between Emergent Biosolutions and Akari Therapeutics

Can any of the company-specific risk be diversified away by investing in both Emergent Biosolutions and Akari Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Emergent Biosolutions and Akari Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Emergent Biosolutions and Akari Therapeutics PLC, you can compare the effects of market volatilities on Emergent Biosolutions and Akari Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Emergent Biosolutions with a short position of Akari Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Emergent Biosolutions and Akari Therapeutics.

Diversification Opportunities for Emergent Biosolutions and Akari Therapeutics

0.57

Correlation Coefficient

Emergent Biosolutions  Akari Therapeutics

Very weak diversification

The 3 months correlation between Emergent and Akari is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Emergent Biosolutions and Akari Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akari Therapeutics PLC and Emergent Biosolutions is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Emergent Biosolutions are associated (or correlated) with Akari Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akari Therapeutics PLC has no effect on the direction of Emergent Biosolutions i.e., Emergent Biosolutions and Akari Therapeutics go up and down completely randomly.

Pair Corralation between Emergent Biosolutions and Akari Therapeutics

Considering the 90-day investment horizon Emergent Biosolutions is expected to under-perform the Akari Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Emergent Biosolutions is 1.6 times less risky than Akari Therapeutics. The stock trades about -0.1 of its potential returns per unit of risk. The Akari Therapeutics PLC is currently generating about 0.14 of returns per unit of risk over similar time horizon. If you would invest  95.00  in Akari Therapeutics PLC on December 22, 2024 and sell it today you would earn a total of  58.00  from holding Akari Therapeutics PLC or generate 61.05% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Emergent Biosolutions  vs.  Akari Therapeutics PLC

Emergent Biosolutions

Risk-Adjusted Performance

Very Weak

Over the last 90 days Emergent Biosolutions has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Akari Therapeutics PLC

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Akari Therapeutics PLC are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Akari Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Emergent Biosolutions and Akari Therapeutics

The main advantage of trading using opposite Emergent Biosolutions and Akari Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Emergent Biosolutions position performs unexpectedly, Akari Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akari Therapeutics will offset losses from the drop in Akari Therapeutics' long position.

The idea behind Emergent Biosolutions and Akari Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.